SM
VRTX icon

SG3 Management’s Vertex Pharmaceuticals VRTX Stock Holding History

SG3 Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,500
Closed -$941K – 1373
2021
Q1 		$967K Sell
4,500
-500
-10% -$110K 0.02% 613
2020
Q4 		$1.18M Sell
5,000
-2,500
-33% -$574K 0.02% 519
2020
Q3 		$2.04M Buy
+7,500
New +$2.07M 0.08% 269

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

SG3 Management's VRTX Position: Q2 2021 in Review

SG3 Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 4,500 shares — an estimated $941K sold.

SG3 Management first reported a position in VRTX in Q3 2020 and held it in 3 quarters. The position peaked at $2.04M in Q3 2020. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

  • SG3 Management reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • SG3 Management sold 4,500 Vertex Pharmaceuticals shares in Q2 2021, an estimated $941K.
  • SG3 Management first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • SG3 Management's Vertex Pharmaceuticals position peaked at $2.04M in Q3 2020.
  • 976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.